论文部分内容阅读
目的探讨归脾丸对慢性特发性血小板减少性紫癜患者血小板相关抗体水平的影响。方法慢性特发性血小板减少性紫癜患者60例,随机分为归脾丸治疗组及西药治疗对照组各30例,应用酶联免疫竞争抑制试验(ELISA)定量测定每组治疗前、治疗后1个月及治疗后3个月的血小板相关抗体水平。结果两组治疗前的PAIgG、PAIgA、PAIgM均无明显差异(P>0.05),经3个月的治疗后再检测两组的PAIgG、PAIgA、PAIgM与各组治疗前相比均有明显下降,有显著意义(P<0.05),两组治疗后的PAIgG、PAIgA、PAIgM相比无明显差异(P>0.05)。结论归脾丸可能通过其组方中的多种药物的免疫抑制或调节作用来抑制慢性特发性血小板减少性紫癜患者血小板相关抗体的产生而达到治疗目的。
Objective To investigate the effect of Guipi Pill on the level of platelet-related antibodies in patients with idiopathic thrombocytopenic purpura. Methods 60 patients with chronic idiopathic thrombocytopenic purpura were randomly divided into Guipiwan treatment group and western medicine control group of 30 cases, enzyme-linked immunosorbent assay (ELISA) quantitative determination of each group before treatment, after treatment 1 Month and 3 months after treatment of platelet-related antibody levels. Results There was no significant difference in PAIgG, PAIgA and PAIgM between the two groups before treatment (P> 0.05). PAIgG, PAIgA and PAIgM in two groups after 3 months of treatment were significantly lower than those before treatment, (P <0.05). There was no significant difference in PAIgG, PAIgA and PAIgM between the two groups after treatment (P> 0.05). Conclusion Guipi Pill may be through the group of prescription drugs in various immunosuppressive or regulatory role in the prevention of chronic idiopathic thrombocytopenic purpura platelet-related antibody production and achieve the purpose of treatment.